MEK1/2-ERK Pathway Alterations as a Therapeutic Target in Sporadic Alzheimer’s Disease: A Study in Senescence-Accelerated OXYS Rats. This evidence concerns the gene MAPK1 and early-onset autosomal dominant Alzheimer disease.